227094-07-7

Basic information

• Product Name: Benzonitrile, 4-(hydroxymethyl)-3-methyl- (9CI)
• Synonyms: Benzonitrile, 4-(hydroxymethyl)-3-methyl- (9CI);4-(HydroxyMethyl)-3-Methylbenzonitrile
• CAS NO: 227094-07-7
• Molecular Formula: C₉H₉NO
• Molecular Weight: 147.17386
• Product Categories: ALDEHYDE
• Mol File: 227094-07-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Benzonitrile, 4-(hydroxymethyl)-3-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-(hydroxymethyl)-3-methyl- (9CI)(227094-07-7)
• EPA Substance Registry System: Benzonitrile, 4-(hydroxymethyl)-3-methyl- (9CI)(227094-07-7)

Safety Data

• Hazardous Substances Data: 227094-07-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Benzonitrile, 4-(hydroxymethyl)-3-methyl(9CI) is used as a key intermediate in organic synthesis for the creation of various chemical compounds. Its unique structure allows it to participate in a range of chemical reactions, making it a valuable component in the synthesis of new molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, Benzonitrile, 4-(hydroxymethyl)-3-methyl(9CI) is utilized as an intermediate in the development and manufacturing of drugs. Its presence in the synthesis process contributes to the formation of active pharmaceutical ingredients, which are essential for the treatment of various medical conditions.
Used in Agrochemical Production:
Benzonitrile, 4-(hydroxymethyl)-3-methyl(9CI) also finds application in the agrochemical sector, where it is employed as an intermediate in the synthesis of pesticides and other agricultural chemicals. Its role in these processes helps to create products that protect crops and enhance agricultural productivity.

Upstream product

• 27609-91-2 4-formyl-3-methyl-benzonitrile 
• 41963-20-6 4-bromo-3-methylbenzonirtile 
• 557-21-1 zinc(II) cyanide 
• 17100-58-2 4-bromo-2-methylbenzyl alcohol 
• 103261-67-2 4-cyano-2-methylbenzoic acid methyl ester 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 

Downstream Products

• 1613413-18-5 methyl 2-[5-[(4-cyano-2-methylphenyl)methoxy]pyrazol-1-yl]pyridine-4-carboxylate 
• 1613411-11-2 2-[5-[(4-cyano-2-methylphenyl)methoxy]pyrazol-1-yl]pyridine-4-carboxylic acid 
• 401947-09-9 4-(aminomethyl)-3-methylbenzene-1-carboximidamide 
• 227094-09-9 4-(azidomethyl)-3-methylbenzonitrile 
• 227094-08-8 (4-cyano-2-methylphenyl)methyl methanesulfonate 

Relevant articles and documents

IMMUNE ADJUSTMENT COMPOUND, USE THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

The present invention provides a compound represented by formula I, wherein R is a halogen element or a C1-C6 alkyl group. The compound has S1 P1 receptor agonist activity and selective specificity and has obviously-shortened half-life in-vivo, and therefore the compound is a high-quality second-generation S1P1 receptor agonist. The present invention also provides a use of the compound in preparing medicine for treating diseases or symptoms mediated by an S1P1 receptor, a pharmaceutical composition comprising the compound, and uses of the compound and the pharmaceutical composition in treating diseases or symptoms mediated by the S1 P1 receptor.

HISTONE DEMETHYLASE INHIBITORS

Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

OXADIAZOLE DERIVATIVES

The invention relates to compounds of formula (I); wherein R1, R2, Ra, Rb, W, Q and S have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple

Novel bicyclic lactam inhibitors of thrombin: Potency and selectivity optimization through P1 residues

Peptidomimetic inhibitors of thrombin lacking the important Ser195-carbonyl interaction have been prepared. The binding energy lost after the removal of the activated carbonyl was recaptured through a series of modifications of the P1 residues of the bicyclic lactam inhibitors. Selected substituted compounds displayed useful pharmacological profiles both in vitro and in vivo.